Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Cash (2023 - 2025)

Historic Change in Cash for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.5 million.

  • Inhibrx Biosciences' Change in Cash fell 966.65% to -$33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 6932.94%. This contributed to the annual value of -$125.3 million for FY2024, which is 318765.71% down from last year.
  • As of Q3 2025, Inhibrx Biosciences' Change in Cash stood at -$33.5 million, which was down 966.65% from -$30.0 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Change in Cash ranged from a high of $144.8 million in Q3 2023 and a low of -$59.4 million during Q4 2023
  • Over the past 3 years, Inhibrx Biosciences' median Change in Cash value was -$30.0 million (recorded in 2025), while the average stood at -$4.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 12107.78% in 2024, then skyrocketed by 35126.37% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Change in Cash (Quarter) stood at -$59.4 million in 2023, then rose by 26.37% to -$43.7 million in 2024, then rose by 23.45% to -$33.5 million in 2025.
  • Its Change in Cash stands at -$33.5 million for Q3 2025, versus -$30.0 million for Q2 2025 and $63.9 million for Q1 2025.